| Added by | mollevi |
|---|---|
| Group name | EquipePM |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Centre Hospitalier Regional Universitaire (CHU) de Montpellier, Montpellier, France. Institut Regional du Cancer de Montpellier (ICM)-Val d'Aurelle, Montpellier, France. IRCM, Institut de Recherche en Cancerologie de Montpellier, Montpellier, France. INSERM, U896, Montpellier, France. Universite Montpellier 1, Montpellier, France. Institut Regional du Cancer de Montpellier, ICM, Montpellier, France. Centre Hospitalier Universitaire (CHU) de Toulouse, TSA, Toulouse Cedex, France. Centre Hospitalier Universitaire (CHU) de Limoges, Limoges Cedex, France. Centre Hospitalier Universitaire (CHU) de Bordeaux, Talence Cedex, France. Institut Claudius Regaud, Toulouse, France. alt-title: Oncotarget number: 14 accession-num: 25918250 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 09:15:34 |
| Date Modified | 2018/07/20 - 09:15:34 |
| Parent item | Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial |
Institut de Recherche en Cancérologie de
